SCYNEXIS, Inc.
SCYNEXIS develops medicines for difficult-to-treat infections in the US. Its lead product candidate is Ibrexafungerp for invasive candidiasis and other fungal infections. It also develops SCY-247 to treat systemic fungal diseases. The company has agreements with GlaxoSmithKline, Merck Sharp & Dohme, Hansoh, R-Pharm, and CJSC for ibrexafungerp development. Formerly known as SCYNEXIS Chemistry & Automation, the company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Overview
Strengths
- Valued below its Drug Manufacturers - Specialty & Generic peers: EV/EBITDA 0.1x vs. a median of 12.9x.
- Cheaper than its own history: EV/EBITDA 0.1x vs. a historical average of 83.5x.
Weaknesses
- Operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 10.0% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 5 of the last 6 years.
- Unstable profitability: operating margin ranged from -1,684% to 52% over the last 5 years, with operating losses in 4 of them.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data